ArticleJTCVS open2026
Sigma-1 receptor agonist SA4503 improves cerebral protective effects in an extracorporeal cardiopulmonary resuscitation rat model.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: In this study, we applied a selective sigma-1 receptor agonist, SA4503, to an extracorporeal cardiopulmonary resuscitation rat model and investigated its cerebral protective effects and potential mechanisms. Methods: Eighteen male adult Sprague-Dawley rats were randomly allocated to 3 groups after anesthesia and identical preparation work, with 6 rats per group. The 2 intervention groups underwent asphyxiation-induced cardiac arrest and were rescued with and without SA4503. The SHAM group did not undergo cardiac arrest or rescue but received the same critical care as the intervention groups until the experiments ended. The end point was 1 hour after the return of spontaneous circulation or death. Hemodynamic and blood gas indicators were measured during surgery. Cerebral injury was evaluated histopathologically. Cerebrospinal fluid samples were collected by microdialysis. Rat hippocampal tissues from the intervention groups were used for whole-transcriptome sequencing. Results: Compared with extracorporeal cardiopulmonary resuscitation (ECPR) group, the ECPR + SA4503 group showed alleviated neuronal destruction of the CA1 region, which is illustrated by the pathologic pictures and the statistical result. In addition, the levels of excitatory amino acids of the ECPR + SA4503 group were lower than that of the ECPR group. In total, 74 differentially expressed genes were detected by RNA sequencing, most of which were related to inflammation, apoptosis, and oxidative stress. The phosphoinositide 3-kinase-AKT signaling pathway was selected by Kyoto Encyclopedia of Genes and Genomes pathway analysis, which may contribute to the cerebral protection of ECPR + SA4503, and was verified via western blotting. Finally, a lncRNA-miRNA-mRNA interactive ceRNA network was established to elucidate the mutual regulation among these three different kinds of RNAs. Conclusions: Our findings indicate that the sigma-1 receptor agonist SA4503 mitigates brain injury in an extracorporeal cardiopulmonary resuscitation rat model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.